Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA7 | P43166 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16212681 | 0.81 | GSK3B (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6999747 | 0.79 | TSHR (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9375759 | 0.77 | MAPT (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3230676 | 0.76 | KDM4E (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17873718 | 0.76 | KMT2A (0.50) | TSHRKDM4EPOLBTDP1L3MBTL1 | |
| SCHEMBL27476911 | 0.75 | CA2 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8493851 | 0.74 | CHEK1 (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2454697 | 0.73 | GSK3B (0.46) | CA1CA2CHEK1METGSK3B | |
| SCHEMBL30300589 | 0.73 | KDM4E (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17202874 | 0.73 | KDM4E (0.42) | CHEK1METGSK3BLIMK1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1200445-B1 | THIENOPYRANECARBOXAMIDE DERIVATIVES | RECORDATI CHEM PHARM (IT) | 2003-09-17 | — | — | EP | disclosed |
| US-20020193381-A1 | Thienopyranecarboxamide derivatives | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY | 2002-12-19 | — | — | US | disclosed |
| US-20020183290-A1 | Adrenergic receptor antagonists selective for both alpha1A-and alpha1D-subtypes and uses therefor | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY | 2002-12-05 | — | — | US | disclosed |
| US-6486163-B1 | Thienopyranecarboxamide derivatives | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2002-11-26 | — | — | US | disclosed |
| WO-2002060534-A2 | SELECTIVE ALPHA 1 ANTAGONISTS A + D | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2002-08-08 | — | — | WO | disclosed |
| US-6387909-B1 | VISION DEFECTS; BENIGN PROSTATIC HYPERPLASIA | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2002-05-14 | — | — | US | disclosed |
| EP-1200445-A1 | THIENOPYRANECARBOXAMIDE DERIVATIVES | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. (IT) | 2002-05-02 | — | — | EP | disclosed |
| US-6306861-B1 | ANTISPASMODIC AGENTS AND TREATMENT OF INCONSTANCE | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2001-10-23 | — | — | US | disclosed |
| WO-2001009140-A1 | THIENOPYRANECARBOXAMIDE DERIVATIVES | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183290-A1 | Adrenergic receptor antagonists selective for both alpha1A-and alpha1D-subtypes and uses therefor | ADRB1, ADRA1D, ADRA1B | CA12 4820/4885CA1 4707/4885CA2 3809/4885 |
| US-20020193381-A1 | Thienopyranecarboxamide derivatives | ADRA1D, ADRB3, OPRD1 | CA12 4640/4885CA1 4059/4885CA2 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.